Search

Author/Creator Lin, W

5. LBA65IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC. (23rd October 2018)

Authors:
Socinski, M A; Rittmeyer, A; Shapovalov, D; Orlandi, F; McCleod, M; Soo, R A; Palmero, R; Kozuki, T; Migliorino, M R; Koynov, K D; Berard, H; Hughes, B G M; Yu, W; Graupner, V; Sun, S W; Kowanetz, M; Hoang, T; Lin, W; Jotte, R M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. LBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. (23rd October 2018)

Authors:
Cappuzzo, F; McCleod, M; Hussein, M; Morabito, A; Rittmeyer, A; Conter, H J; Kopp, H-G; Daniel, D; McCune, S; Mekhail, T; Zer, A; Reinmuth, N; Sadiq, A; Archer, V; Ochi Lohmann, T; Wang, L; Kowanetz, M; Lin, W; Sandler, A; West, H
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. LBA9IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. (25th November 2018)

Authors:
Mok, T S K; Socinski, M A; Reck, M; Jotte, R M; Lim, D W-T; Cappuzzo, F; Orlandi, F J; Stroyakovskiy, D; Nogami, N; Rodríguez-Abreu, D; Moro-Siblot, D; Thomas, C A; Barlesi, F; Finley, G; Lee, A; Shankar, G; Yu, W; Kowanetz, M; Lin, W; Nishio, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). (25th November 2018)

Authors:
Mok, T S K; Reck, M; Horn, L; Lam, S; Shames, D S; Liu, J; Kabbinavar, F; Lin, W; Sandler, A; Liu, S V
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. 1386PDIMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC. (23rd October 2018)

Authors:
Reck, M; Wehler, T; Orlandi, F; Nogami, N; Barone, C; Moro-Sibilot, D; Shtivelband, M; González Larriba, J L; Rothenstein, J; Frueh, M; Shankar, G; Lee, A; Deng, Y; Patel, H; Kelsch, C; Lin, W; Socinski, M A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗